The QualityStocks Daily Monday, April 18th, 2022

Today's Top 3 Investment Newsletters

QualityStocks(LCLP) $0.0094 +147.37%

MarketClub Analysis(CASA) $7.1000 +82.52%

BeatPennyStocks(PDPG) $0.0435 +45.00%

The QualityStocks Daily Stock List

Enservco (ENSV)

StockMarketWatch, QualityStocks, Streetwise Reports, InvestorPlace, MarketClub Analysis, MarketBeat, StreetInsider, FeedBlitz, BUYINS.NET, Zacks, Wall Street Resources, TradersPro, The Bowser Report, Lions of Wall Street and Investing Futures reported earlier on Enservco (ENSV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Enservco Corporation (NYSE American: ENSV) (FRA: A3O0) is engaged in the provision of fluid management as well as enhancement servicers to the onshore natural gas and oil industry in the U.S.

The firm has its headquarters in Longmont, Colorado and was founded in 1980 on February 28th by Michael D. Herman. It operates in the energy sector, under the oil and gas sub-industry. Additionally, it operates in the following regions: the Central United States region, which includes the Permian Basin and Eagle Ford Shale in Texas; the Rocky Mountain region, which is made up of eastern Montana, western North Dakota, central Wyoming, southern Wyoming and western Colorado; and the eastern U.S. region which includes eastern Ohio’s Utica Share formulation and the Marcellus Shale formation’s southern region as well as Pennsylvania, Oklahoma, New Mexico and Kansas.

The company operates through the Completion and other services and the Production services segment. The former segment is involved in the provision of frac water heating services and associated support services to the domestic gas and oil industry. On the other hand, the latter segment uses a fleet of acidizing and hot oil trucks to offer maintenance services to the domestic gas and oil industry.

The enterprise operates and owns a fleet of about 330 frac tanks, trailers, and specialized trucks. It provides well site construction, frac tank rental, fluid disposal, saltwater and freshwater hauling, scale and bacteria treatment, acidizing, pressure testing, hot oiling and frac water heating services.

The firm recently entered into partnerships with a duo of major oilfield services companies in the 1st quarter, which will bring in more investment opportunities for the company. The firm’s CEO also revealed that they would be focusing on the hot oiling service business, noting that there was potential for expansion in the space and the move would bring in additional revenue.

Enservco (ENSV), closed Monday's trading session at $3.63, up 38.0228%, on 16,486,240 volume with 45,920 trades. The average volume for the last 3 months is 16.283M and the stock's 52-week low/high is $0.5502/$8.76.

Good Gaming (GMER)

Penny Stock Mobsters, QualityStocks, WallstreetSurfers, SizzlingStockPicks, POSstocks, OnPointStockAlert, Stockgoodies, PennyPickAlerts, Fortune Stock Alerts, Wall Street Mover, ProTrader, PoliticsAndMyPortfolio, PennyStock Tweets and PennyDoctor reported earlier on Good Gaming (GMER), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Good Gaming Inc. (OTC: GMER) is a firm that is engaged in the provision of online gaming platform services to active gamers.

The firm has its headquarters in Kennett Square, Pennsylvania and was incorporated in 2008 on November 3rd. It operates as part of the advertising and marketing services industry, under the technology sector in the software and tech services industry, under the software sub-industry.

The enterprise uses its technology platform to provide vendors and publishers an approach to gaming interactions. Its platform enables integration into other existing systems and the integration of 3rd party applications. Additionally, the framework enables guilds/teams/clans to interact which each other, communicate and add functionality over a period of time to include running their own tournaments leveraging the online communities’ viral nature.

The company is an online destination and leading tournament gaming platform that targets more than 250 million amateur gamers globally who would like to compete at the college or high school level. It offers content aggregation, e-sports venues and tournament hosting. This is in addition to engaging in the development of Minecraft servers. The company is also involved in the cryptocurrency business through its Crypto Strategies Group and provides articles, videos and blogs authored by world-renowned professional gamers.

The firm is expanding its business operations to include blockchain digital assets called NFTs (non-fungible tokens). It recently announced that it was planning to launch an online game that will allow gamers to profit from the firm’s cryptocurrency, known as GOO. This will extend its consumer reach and increase investments into the firm.

Good Gaming (GMER), closed Monday's trading session at $0.071, up 47.2418%, on 3,448,412 volume with 272 trades. The average volume for the last 3 months is 3.448M and the stock's 52-week low/high is $0.0163/$0.75.

Life Clips (LCLP)

TechStockInsider, QualityStocks, The Observer, Stock Commander, OTC Stock Review, theOTC.today, Promotion Stock Secrets and Broad Street reported earlier on Life Clips (LCLP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Life Clips Inc. (OTC: LCLP) is engaged in the development, manufacture and sale of batteries and action cameras.

The firm has its headquarters in Aventura, Florida and was incorporated in 2013, on March 20th by Hannah Grabowski. Prior to its name change, the firm was known as Blue Sky Media Corporation. It has two companies in its corporate family and serves consumers in the United States as well as internationally.

The enterprise is focused on marketing Mobeego and KP branded products and holds a sublicense to display, reproduce and use the HP trademarks in different territories. Its products include still cameras, dash cameras, body cameras, 360° cameras and HP branded action cameras. Its action cameras are designed for multiple recordings and live streaming of video. In addition to this, the enterprise not only develops but also distributes cordless and single-use batteries under the Mobeego brand, which can be used by cellular phones as well as other mobile devices. It also produces the adapter and the Energy Unit (Battery). The energy unit comprises of a custom designed plastic casing which hosts a lithium battery.

The company also develops an auditable software for law enforcement and sells its products online as well as through distributors and retailers.

It recently entered into an agreement to acquire a global blockchain tech firm by the name of Belfrics Group. Its CEO notes that having this firm operating as a Life Clips subsidiary will be beneficial to the company’s shareholders and help grow the company’s platform, which will be good for investments.

Life Clips (LCLP), closed Monday's trading session at $0.0094, up 147.3684%, on 198,117,877 volume with 1,781 trades. The average volume for the last 3 months is 198.118M and the stock's 52-week low/high is $0.0016/$0.0738.

Motorsport Games (MSGM)

MarketBeat reported earlier on Motorsport Games (MSGM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Motorsport Games Inc. (NASDAQ: MSGM) is a motorsport network firm that is focused on the development and publishing of multi-platform racing video games.

The firm has its headquarters in Miami, Florida and was incorporated in August 2018. It operates as part of the electronic gaming and multimedia industry, under the communication services sector. The firm has twenty-seven companies in its corporate family and serves consumers around the world.

The company operates through the E-sports and Gaming segments. The E-sports segment is involved in organizing and facilitating e-sports events, competitions and tournaments for licensed racing games, as well as on behalf of other video game publishers and 3rd party video game racing series. On the other hand, the Gaming segment is involved in the development and publishing of interactive racing video games and entertainment services and content. The company operates as a Motorsport Network LLC subsidiary.

The enterprise provides video games for mobile platforms, personal computer platforms and game consoles through a number of digital and retail channels, which include downloadable and full-game content. It also provides motorsport racing series including BTCC (the British Touring Car Championship) and NASCAR. The enterprise is also an e-sports partner of choice for BTCC, Formula E, 24 Hours of Le Mans, NASCAR and the FIA World Rally Cross-Championship. It sells its video game products via various digital and retail channels.

The firm expects to accelerate its growth as well as increase its revenues significantly, which will help create value for its shareholders and bring in more investments into the firm.

Motorsport Games (MSGM), closed Monday's trading session at $1.14, off by 5%, on 122,723 volume with 498 trades. The average volume for the last 3 months is 122,723 and the stock's 52-week low/high is $1.08/$22.65.

Peraso Inc. (PRSO)

We reported earlier on Peraso Inc. (PRSO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Peraso Inc. (NASDAQ: PRSO) (FRA: N6Z0) is a fabless semiconductor firm that is focused on the development, marketing and sale of semiconductor modules and devices.

The firm has its headquarters in San Jose, California and was incorporated in 1991. Prior to its name change in December 2021, the firm was known as MoSys Inc. It operates as part of the semiconductors industry, under the technology sector. The firm serves consumers around the globe.

The company operates through the Taiwan, Hong Kong, North America and Rest of the World segments. It is mainly focused on developing mmWave (millimeter wavelength) for 5G cellular networks and for the 60 gigahertz spectrum.

The enterprise’s products include programmable hyper-speed engines which enable user-defined algorithms or functions; and accelerator engine products consisting of bandwidth engine for high performance applications whether output is crucial. It also offers mmWave modules; and mmWave ICs, including different mmWave radio frequencies, baseband IC, integrated circuits and associated antenna technology. Its mmWave products allow a number of applications, including consumer applications like untethered virtual reality and augmented reality and wireless video streaming, as well as 5G with low latency and high reliability. The enterprise also provides quad partition rate which enables parallel accesses to multiple partitions. This is in addition to providing non-recurring engineering services and licensing intellectual property. It markets its products via sales representatives and distributors, as well as directly through its sales personnel.

The company remains focused on broadening its portfolio of mmWave solutions and meeting consumer requirements, which will bolster its earnings as well as its growth.

Peraso Inc. (PRSO), closed Monday's trading session at $2.02, off by 6.0465%, on 83,032 volume with 255 trades. The average volume for the last 3 months is 82,833 and the stock's 52-week low/high is $1.74/$10.75.

Qurate Retail Inc. (QRTEA)

Schaeffer's, MarketClub Analysis, MarketBeat, InvestorPlace, Kiplinger Today, Wealth Insider Alert, Trades Of The Day, The Street, StreetInsider, StockMarketWatch and Daily Trade Alert reported earlier on Qurate Retail Inc. (QRTEA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Qurate Retail Inc. (NASDAQ: QRTEA) (LON: OA4G) is involved in the business of online and video commerce industries.

The firm has its headquarters in Englewood, Colorado and was incorporated in 1991, on March 28th. Prior to its name change in April 2018, the firm was known as Liberty Interactive Corp. It operates as part of the internet retail industry, under the consumer cyclical sector. The firm serves consumers across the globe.

The company operates through the QVC International, QxH and Corporate and Others segments. The corporate segment includes the company’s Cornerstone subsidiary, along with different cost and equity method investments. The international segment focuses on distributing a shopping experience through social pages, mobile applications, websites and broadcast networks in Italy, the Republic of Ireland, the United Kingdom, Japan, Austria and Germany. On the other hand, the QxH segment is involved in distributing live programming to television households.

The enterprise operates as an online retailer offering men’s, women’s and children’s apparel and other products, including beauty products, accessories and home through its desktop, app and mobile applications. It also markets and sells different consumer products mainly through merchandise-focused televised shopping programs, mobile applications and internet. The enterprise serves roughly 200 million homes around the globe through fourteen television networks, reaching millions more through print catalogs, websites, mobile applications and in-store destinations.

The company, which already comprises of a number of leading retail brands, remains focused on growing its market share and bolstering its growth, which will be good for its revenues and help create shareholder value.

Qurate Retail Inc. (QRTEA), closed Monday's trading session at $4.39, off by 0.902935%, on 3,572,830 volume with 17,380 trades. The average volume for the last 3 months is 3.573M and the stock's 52-week low/high is $4.30/$14.62.

Sonendo Inc. (SONX)

MarketBeat reported earlier on Sonendo Inc. (SONX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sonendo Inc. (NYSE: SONX) is a commercial-stage medical technology firm that is focused on the development, manufacture and commercialization of devices for root canal therapy.

The firm has its headquarters in Laguna Hills, California and was incorporated in 2006. Prior to its name change in March 2011, the firm was known as Dentatek Corp. It operates as part of the medical devices industry, under the healthcare sector. The firm has three companies in its corporate family and serves consumers around the globe, with a focus on Canada and the United States.

The company’s mission is to save teeth and prevent the progression of tooth decay. It does so by enabling superior disinfection and cleaning of the root canal system with a streamlined workflow for practices and minimal post-operative pain for individuals.

The enterprise provides a practice management software known as the Digital Office, which enables an integrated digital office for dental practitioners. It also provides a material used to create a seal platform on top of the tooth crown, dubbed SoundSeal; and a branded EDTA liquid solution which is used to help disinfect the root canal system. In addition to this, the enterprise offers a tooth decay treatment device for disinfecting and cleaning the microscopic spaces between teeth known as GentleWave.

The firm is focused on increasing the adoption of its GentleWave System, which has numerous clinical benefits, especially in comparison to current methods of root canal therapy. This will not only bring in additional revenues but also extend its consumer reach, which will positively influence investments.

Sonendo Inc. (SONX), closed Monday's trading session at $3.02, up 5.2265%, on 88,688 volume with 670 trades. The average volume for the last 3 months is 88,688 and the stock's 52-week low/high is $2.60/$12.24.

T Stamp Inc. (IDAI)

We reported earlier on T Stamp Inc. (IDAI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

T Stamp Inc. (NASDAQ: IDAI) is an artificial intelligence firm that is focused on the development and marketing of identity authentication software solutions for peer-to-peer markets and enterprise partners.

The firm has its headquarters in Atlanta, Georgia and was incorporated in 2015 by Mike Lindenau, Catherine Lambert, Andrew Gowasack and Gareth Genner. It operates as part of the software-application industry, under the technology sector. The firm serves consumers across the globe, with a primary focus on the United Kingdom, Malta and the United States.

The enterprise uses the cutting-edge power and agility of technologies like edge computing, neural networks and graphics processing unit to process data effectively for usage in various industries. Its AI-powered solutions include data mining, cryptography, researching and leveraging biometric science, to deliver insightful trust and identity predictions while also guarding against and identifying fraudulent attacks. Its solutions convert identification data like biometrics into a transformed identity token which is used as a secure tokenized identity. It also provides solutions for biometric capture, duplicate detection, identity verification, document validation, data protection and privacy. The enterprise serves the healthcare, travel and real estate; sharing economy, social media and P2P transactions; government and law enforcement; KYC/AML compliance (Know Your Customer/Anti-Money Laundering compliance); biometrically secured email; humanitarian and development services; and the banking/fintech industries.

The company recently entered into a partnership with VIVA Finance, which will involve providing support to equitable and accessible financial systems, as the basis for global inclusion. This move will not only expand the impact and reach of the company’s solutions but also bring in additional investments and revenues.

T Stamp Inc. (IDAI), closed Monday's trading session at $2.24, off by 8.9431%, on 5,265 volume with 42 trades. The average volume for the last 3 months is 5,265 and the stock's 52-week low/high is $1.01/$10.00.

Gratomic Inc. (CBULF)

QualityStocks and equities Canada reported earlier on Gratomic Inc. (CBULF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gratomic (TSX.V: GRAT) (OTCQX: CBULF) (FSE: CB82) today announced the addition of Fernando Luís Pereira Calha to the executive team. Calha is experienced in strategic operations and business-to-business development in the field of technical solutions, with a focus on measurable and sustainable results. He will serve as the company's new director of graphite sales and business development, responsible for establishing a working relationship between Gratomic and its targeted end users through tailored product offerings and price strategies aimed at seizing the largest possible market share by ensuring a complete and current understanding of existing players and their unique requirements.

Calha will manage daily contacts with existing and potential customers, as well as the negotiation and execution of strategic supply contracts and offtakes. In addition, he will liaise with institutional market entities, ensuring that Gratomic is always up to date with the latest developments.

To view the full press release, visit https://ibn.fm/LxyRx

About Gratomic Inc.

Gratomic is a multinational company with projects in Namibia, Brazil and Canada. The company is focused on becoming a leading global graphite supplier and aims to secure a strong position in the electric vehicle (“EV”) battery supply chain. With the continued development of its flagship Aukam project and further exploration on the company's Capim Grosso property, Gratomic sets itself apart by seeking out unique top-quality assets around the world. True to its roots, the company will continue to explore graphite opportunities displaying potential for development.

Large quantities of high-quality vein graphite have been shipped for testing to confirm its viability as an anode material. Gratomic is confident that the test results will provide a unique competitive advantage in its desired target markets. The company will continue to update the public on the status of these tests and will provide results as soon as they become available. The company has formed a collaboration agreement with Forge Nano. With its patented Atomic Layer Deposition (“ALD”) coating, this cooperation with Forge Nano is a key element to support Gratomic's strategies towards the value-added phases of production of graphite for anode applications, namely micronization, spheronization and coating, making Gratomic graphite a preferred choice for use in lithium-ion batteries. For more information about the company, visit www.Gratomic.ca.

Gratomic Inc. (CBULF), closed Monday's trading session at $0.58, off by 4.918%, on 35,088 volume with 41 trades. The average volume for the last 3 months is 35,088 and the stock's 52-week low/high is $0.532224/$1.50.

Aura FAT Projects Acquisition Corp. (AFARU)

We reported earlier on Aura FAT Projects Acquisition Corp. (AFARU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aura FAT Projects Acquisition (NASDAQ: AFARU) announced the pricing of its initial public offering — the pricing is $100 million and is comprised of 10 million units, with each unit priced at $10. According to the announcement, the units should be listed on the Nasdaq Global Market to trade under the ticker symbol “AFARU.”

The offering units will each consist of one Class A ordinary share and one redeemable warrant; the warrant would entitle the holder to purchase one additional Class A ordinary share at a price of $11.50. When the units begin trading separately, it is anticipated that the Class A ordinary shares and warrants will to be listed under the symbols “AFAR” and “AFARW”, respectively.

To view the full press release, visit https://ibn.fm/h9q2t

About Aura FAT Projects Acquisition Corp.

Aura FAT Projects is a newly organized blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While it will not be limited to a particular industry or geographic region, the company intends to focus its search on new emerging technology companies with an acute growth potential in Southeast Asia and Australasia in sectors such as the Web 3.0, blockchain, cryptocurrency, digital ledger, e-gaming and other new financial technology and services sectors.

Aura FAT Projects Acquisition Corp. (AFARU), closed Monday's trading session at $9.99, up 0.050075%, on 599,510 volume with 290 trades. The average volume for the last 3 months is 599,510 and the stock's 52-week low/high is $9.95/$10.00.

Magenta Therapeutics Inc. (MGTA)

MarketBeat, Trades Of The Day, StreetInsider, Daily Trade Alert, The Online Investor, StockMarketWatch, Schaeffer's, QualityStocks, InvestorPlace and BUYINS.NET reported earlier on Magenta Therapeutics Inc. (MGTA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Magenta Therapeutics (NASDAQ: MGTA) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We are updating our MGTA company model after assuming research coverage of the company and also incorporating updates related to the company's revised operating plan. We agree with their efforts to emphasize the MGTA-117 targeted conditioning program, given its potentially transformative nature.

Management will also continue IND-enabling activities for their CD45-ADC and MGTA-145 stem cell mobilization efforts in sickle cell disease but will de-prioritize other investments to navigate the challenging capital market environment and extend their expected cash runway into 2Q 2024 (from 4Q 2023). Our model updates lower our DCF-derived price target to $8 (from $17), but we maintain our Buy rating given the potential upside from the current valuation.”

To request access to the full report, visit https://ibn.fm/f1ahI

About Magenta Therapeutics Inc.

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines designed to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise to revolutionize immune and blood reset to allow more patients to take advantage of the curative potential of stem cell transplant as well as potentially improve eligibility for future gene therapies. Magenta is based in Cambridge, Mass. For more information, visit the company’s website at www.Magentatx.com.

Magenta Therapeutics Inc. (MGTA), closed Monday's trading session at $1.92, off by 14.2857%, on 188,157 volume with 2,124 trades. The average volume for the last 3 months is 188,154 and the stock's 52-week low/high is $1.91/$13.22.

Southern Copper Corporation (SCCO)

SmarTrend Newsletters, MarketBeat, The Street, InvestorPlace, Louis Navellier, The Online Investor, Daily Wealth, Daily Trade Alert, TopStockAnalysts, Trades Of The Day, StreetAuthority Daily, Zacks, Marketbeat.com, The Wealth Report, Barchart, TheStockAdvisor, Money Morning, Schaeffer's, Market Intelligence Center Alert, Market Authority, Top Pros' Top Picks, Uncommon Wisdom, The Growth Stock Wire, Investopedia, MarketClub Analysis, Kiplinger Today, INO.com Market Report, StreetInsider, ChartAdvisor, TheStockAdvisors, The Stock Enthusiast, Early Bird, Investor Update, Investiv, InvestmentHouse, Investing Futures, DrStockPick, Dividend Opportunities, CRWEPicks, Greenbackers, CRWEFinance, Forbes, BestOtc, AllPennyStocks, CRWEWallStreet, StockLockandLoad, Wealth Insider Alert, Wealth Daily, Vantage Wire, TradingMarkets, TradingAuthority Daily, The Tycoon Report, The Trading Report, The Motley Fool, MarketDNA, StockRockandRoll, InvestorGuide, StockHotTips, Profit Confidential, PennyToBuck, PennyOmega, Navellier Growth, Money and Markets, 24/7 Trader, InvestorsObserver Team, InvestorIntel and Streetwise Reports reported earlier on Southern Copper Corporation (SCCO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Strategists at JPMorgan Chase predict that commodities are likely to witness a price surge of up to 40% this year if investors elect to pour more money into natural resources in a timeframe characterized by increasing inflationary pressures. If such a price hike occurs, commodities will enter record-breaking price levels.

The JPMorgan strategists say that at the moment, investor allocations in the raw materials segment exceed the average allocations on record historically. However, the situation at the moment cannot be described as “overweight.” Consequently, there is still room for massive funding to flow into raw materials and trigger the surge in prices foreseen by the investment bank.

So far, the biggest surge in the price of commodities was witnessed in March when Russia invaded its neighbor Ukraine. This price boost happened for commodities ranging from wheat and fertilizers to crude oil. As a result, inflation around the world went up a notch, and the U.S. Federal Reserve was prompted to take action.

That mix of rising commodity prices, inflationary pressures and action by the Fed is causing investors to begin rethinking the balance of their investment portfolios. Many investors are likely to rethink their portfolios in favor of commodities or raw materials, according to the JPMorgan analysts. This is particularly likely given that the urge to hedge against inflation is strong, and commodities seem to be the likely asset class to offer that hedge.

In a note published on April 6, 2022, the strategists at JPMorgan Chase say that it is likely that the investments in commodities are likely to grow to 1% of all financial assets across the globe, and this allocation would be higher than the previous highest percentage recorded. If all other factors remain constant, that increase in investments allocated to commodities could result in a 30% to 40% rise in commodity prices, the JPMorgan strategists say.

When one considers what is currently happening, the prediction by JPMorgan doesn’t seem so outlandish. For example, Brent crude, the benchmark for oil prices around the world, has increased in excess of 30%. As a result, the price of Brent crude has hit a level that was last recorded in 2008. Energy, metals and crops have also seen massive price gains.

JPMorgan isn’t alone in being bullish about commodities. For example, Goldman Sachs also warned earlier this month that there is likely to be a supply shock in the copper value chain, and the investment bank is notable for its consistency in seeing a bull run for raw materials. These predictions paint a positive picture for what extraction companies such as Southern Copper Corporation (NYSE: SCCO) can expect in the foreseeable future.

Southern Copper Corporation (SCCO), closed Monday's trading session at $73.22, up 0.590741%, on 597,590 volume with 11,260 trades. The average volume for the last 3 months is 593,698 and the stock's 52-week low/high is $54.92/$83.29.

The QualityStocks Company Corner

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • Lexaria’s patented DehydraTECH(TM) technology has proven, in the NIC-A21-1 animal study, to be 10-20 times faster in reaching peak delivery of nicotine to the bloodstream than controls
  • The company hopes to affirm this in the NIC-H22-1 human nicotine study as their DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States such as ON! and Zyn
  • Lexaria has separately announced new agreements with Altria that will see the company receive a fee to provide certain DehydraTECH powder-based nicotine formulations that Altria will evaluate
  • The company hopes that this, coupled with the human clinical study, will confirm that purified nicotine with DehydraTECH leads to better oral tissue absorption and reduced negative experiences relative to existing brands

Lexaria Bioscience (NASDAQ: LEXX) has made a name for itself as a global innovator in drug delivery platforms. Its patented DehydraTECH(TM) technology, promotes fast-acting, less expensive, and more effective oral drug delivery, proven through in vivo, in vitro, and human clinical testing.

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.  DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Monday's trading session at $4.05, up 5.7441%, on 1,186,948 volume with 5,801 trades. The average volume for the last 3 months is 1.187M and the stock's 52-week low/high is $3.91/$27.50.

Recent News

Kaival Brands Innovations Group Inc. (KAVL)

The QualityStocks Daily Newsletter would like to spotlight Kaival Brands Innovations Group Inc. (KAVL).

Kaival Brands (NASDAQ: KAVL), the exclusive global distributor of all products made by Bidi(R) Vapor LLC, including the BIDI(R) Stick disposable electronic nicotine delivery system ("ENDS"), is expanding its distribution by adding both wholesale and retail accounts. Kaival anticipates the new distribution footprint will cover an estimated 28,000 additional stores. The announcement comes after the U.S. Food and Drug Administration issued a marketing denial order ("MDO") to Bidi Vapor last year, as it did for some 96% of all manufacturers of flavored ENDS. However, earlier this year the U.S. Court of Appeals for the Eleventh Circuit granted Bidi Vapor a judicial stay of the MDO, while the courts determine the result of Bidi Vapor's ongoing merits-based litigation. “We are encouraged by growing sales volumes in our second fiscal quarter generated by both established wholesalers and retailers selling the BIDI Stick in new stores, as well as new wholesale and retail accounts being added to our distribution network,” said Kaival Brands CEO Niraj Patel in the press release. “We anticipate the activation of approximately 3,900 new store locations over the next 45 days, including one new major retailer having already placed orders totaling more than $1.1 million. . . . The judicial stay granted in February allowed us to resume sale of all 11 flavored products in the BIDI Stick lineup. We are eager to return our flavored products to the shelves of retailers that comply with the Prevent All Cigarette Trafficking Act so adult consumers can enjoy their preferred flavors once again. As a result of the judicial stay, we expect revenues to resume an upward trajectory as renewed distribution ramps up and sales of flavored BIDI Sticks increase.” To view the full press release, visit https://ibn.fm/RPzNV

Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) is a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. Its vision is to develop internally, acquire, own or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. In line with this vision, Kaival Brands is the exclusive global distributor of all products manufactured by Bidi Vapor LLC, which are intended exclusively for adults 21 and over.

Kaival Brands is on a mission to set the highest standard and elevate the adult consumer experience for vaping. The company is headquartered in Grant, Florida.

Bidi® Stick

Bidi® Stick, Bidi Vapor LLC’s primary offering, is the fastest-growing closed system disposable electronic nicotine delivery system (ENDS) in the U.S.

Intended exclusively for adults 21 and over, the one-time use device is designed with premium features, including a high-quality battery, satisfying Class A nicotine offering consistently smooth throat hits and an aluminum body. Bidi Stick is ready to use straight from the package, providing a consistent and precise amount of nicotine with every draw.

Bidi Stick and all Bidi Vapor products are sold primarily through national convenience stores, as well as online exclusively through authorized direct retailers and GoPuff, the digital convenience store.

Bidi® Cares Initiative

The tamper-resistant Bidi Stick is the only ENDS on the market with an ecologically friendly, mass-recycling program. The Bidi® Cares initiative focuses on promoting sustainable practices to save the environment, one step at a time, through proper disposal of vapor products.

Through Bidi Cares, Kaival Brands and Bidi Vapor aim to promote and educate consumers on the dangers of improper waste disposal.

Bidi® Pouch

On January 26, 2021, Kaival Brands took a step toward building on the success of Bidi Vapor’s e-cigarette device when it announced the debut of the Bidi® Pouch. Officially launching in early February, the Bidi Pouch provides a tobacco-free nicotine formulation packed in an easy-to-go tin can, available in six flavors.

“We are excited that Bidi Vapor continues to develop and innovate new ways to bring the Bidi Vapor experience to adult consumers. Bidi Vapor’s new Bidi Pouch offering, which we will exclusively distribute, is just another example of our ability to meet the demands of the marketplace,” Niraj Patel, CEO of Kaival Brands, stated in the news release. “The pouch marketplace is yet another opportunity to demonstrate Bidi Vapor’s premium experience to adult users. We believe that Bidi Vapor’s share of the nicotine pouch market will rival Bidi Vapor’s market share achievement in vape. It represents a significant opportunity for us as the exclusive distributor of Bidi Vapor’s products in 2021 and beyond.”

Recent Corporate Developments

  • March 1, 2021: Kaival Brands announced its entry into two new distribution agreements boosting the company’s potential store count for Bidi Vapor products to over 54,000 – a 500% increase over 2020. Patel noted in the news release that this milestone, along with recent corporate developments, has the company “feeling extremely confident about [its] fiscal year 2021 revenue guidance range of $400m – $450 million.”
  • March 16, 2021: The company reported $37.4 million in revenue for the fiscal quarter ended January 31, 2021. This figure brought its cumulative revenues since commencing business operations in March 2020 to roughly $100 million, despite revenue slowdowns during the fourth quarter of 2020 as a result of packaging and labeling updates. Patel forecast an increase to revenues during Kaival Brands’ second fiscal quarter ending April 31, 2021. He also reaffirmed the company’s confidence in its fiscal 2021 revenue guidance.
  • March 18, 2021: Kaival Brands announced its appointment of three new directors to its board ahead of its proposed uplisting to the Nasdaq Capital Market. The appointments of Paul Reuter, Carolyn Hanigan and Roger Brooks as independent directors are intended to ensure the company complies with certain Nasdaq corporate governance rules.
  • March 31, 2021: The company announced that Bidi Vapor LLC has successfully completed the regulatory process to enter four new, significant markets – the U.K., Australia, New Zealand and Russia.

Market Outlook

The U.S. e-cigarette and vape market was valued at $6.09 billion in 2020, according to data from Grand View Research. The firm expects the industry to expand at a compound annual growth rate of 27.3% from 2021 to 2028, with growth factors including rising awareness of tobacco alternatives.

Management Team

Nirajkumar Patel is the CEO, CFO, President, Treasurer and Director of Kaival Brands and owner of Bidi Vapor LLC. In 2004, Patel received a Bachelor of Science in pharmaceutical sciences from AISSMS College of Pharmacy in Pune, India. He moved to the United States in 2005, and he continued his education at the Florida Institute of Technology, where he graduated in 2009 with a master’s degree in medicinal and pharmaceutical chemistry. He currently holds a Six Sigma Black Belt Certification.

Eric Mosser is the COO, Secretary and Director of Kaival Brands. Mosser attended Arizona State University, where he studied business management. In 2004, he graduated from Rio Salado College with an associate degree in applied science in computer technology.

Paul Reuter is a Director of Kaival Brands. He brings to the company nearly five decades of industry experience in small box retail as a journalist, editorial director, entrepreneur and speaker. Mr. Reuter has launched two successful businesses, including MidWest Retail Group LLC, which was the largest U.S. 7-Eleven franchise group, where he served as Chairman and founding partner from April 2013 through June 2019. He is also the founder of Kreative Collaborations LLC, an industry consultancy.

Carolyn Hanigan is a Director of Kaival Brands. She served as the President of Reynolds American Innovation Company, an operating company of Reynolds American Inc. (“RAI”), from January 2016 to June 2018. Ms. Hanigan also led the global vapor collaboration with British American Tobacco (“BAT”) up until RAI was acquired by BAT in 2017. She served as the architect of RAI’s U.S. reduced risk products strategic direction to further the vision of transforming tobacco, preparing the U.S. commercial execution and regulatory applications for a wide array of products, including the Glo tobacco heating products; the Velo nicotine pouches; and the Alto, Ciro, Vibe and Solo nicotine vaporizers. Ms. Hanigan holds a Bachelor’s degree in business from Boston College and a Master of Business Administration degree from St. Mary’s College.

Roger Brooks is a Director of Kaival Brands. Since 2005, he has served as the Chairman, Treasurer and Co-Founder of Abierto Networks. Prior to his roles with Abierto, Mr. Brooks was the lead independent director and a member of the compensation and audit committees for Moldflow Corporation, a Nasdaq-listed software firm that was sold to Autodesk Inc. in 2008. He holds a Bachelor of Arts degree from the University of Connecticut and a Master of Business Administration degree from New York University, Stern Graduate Business School. He is also a graduate of the Stanford University Executive Management Program.

Kaival Brands Innovations Group Inc. (KAVL), closed Monday's trading session at $1.37, up 13.2231%, on 1,283,840 volume with 2,837 trades. The average volume for the last 3 months is 1.284M and the stock's 52-week low/high is $3.53/$7.29.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM), a rare cannabinoid drug developer, is expanding its product manufacturing scale, thanks largely to the acquisition of consumer-focused rare cannabinoids manufacturer BayMedica last year. “InMed’s most-recent Q2 financial statement reported revenues of $0.3 million from commercial sales of cannabichromene (‘CBC’) to the health and wellness market following the BayMedica acquisition. Since January, the company has also been selling cannabicitran (‘CBT’) to the health and wellness market on a B2B basis,” a recent article reads. “The company’s forward-looking focus on bringing new cannabinoid products to commercial scale anticipates scales of cannabidivarin (‘CBDV’) and tetrahydrocannabivarin (‘THCV’) in the coming months as its next revenue generators…. The company expects to produce more than 100 kilograms of CBDV and THCV under the initiative. Because of the very limited quantities of rare cannabinoids that make them effectively impractical from an economic standpoint to extract directly from the plant for pharmaceutical use, InMed’s R&D operation is working to develop synthetic formulations for the treatment of specific conditions.” To view the full article, visit https://cnw.fm/fTNC8

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Monday's trading session at $0.9272, up 6.2206%, on 44,207 volume with 261 trades. The average volume for the last 3 months is 44,205 and the stock's 52-week low/high is $2.64/$12.50.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, today announced that its Robot Roadshow will land at the Hollywood Casino in Aurora, Illinois, on April 19-20 from 10:00 a.m. to 2:00 p.m. CT, and at Digby’s Detective & Security Agency in Chicago, Illinois, on April 21, 2022, from 10:00 a.m. to 2:00 p.m. CT. A Knightscope expert virtually attends each Roadshow landing, and visitors will have the opportunity to see the Knightscope Security Operations Center (“KSOC”) user interface in action and interact directly with each of the company’s autonomous security robots. The announcement reads, “The Robot Roadshow has made 37 landings in 12 states to date. Knightscope’s crime-fighting robots tour the U.S. in a space-age, NASA-like ‘pod’ allowing attendees to experience all the technology that is enabling these autonomous security robots (‘ASRs’) to help make sites safer today from Hawaii to Texas to North Carolina. A short video of a past event hosted by the Los Angeles Police Department may be viewed here: https://vimeo.com/645787920.” There is no charge to participate in or visit the Roadshow, and available slots fill up fast. Appointments are recommended and can be made by visiting the following link: https://calendly.com/robotroadshow/. To view the full press release, visit https://ibn.fm/OZKUL

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at www.knightscope.com/crime

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at www.knightscope.com/investors

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at www.knightscope.com/ksoc

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at www.knightscope.com/roadshow

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Monday's trading session at $4.77, off by 1.2422%, on 152,365 volume with 1,089 trades. The average volume for the last 3 months is 151,143 and the stock's 52-week low/high is $0.66/$4.90.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance MMT(R) lidar solutions, announced the appointment of Paul Anawalt to the newly created position of general counsel, effective today. Anawalt joins Cepton from the Intel Corporation and is a seasoned lawyer with more than 25 years of business and technology law experience, serving as in-house and outside counsel. He has advised public and private companies on strategy, technology transactions, IP, securities, mergers and acquisitions and other areas. “I am grateful for the opportunity to lead the legal organization of Cepton and excited to help strengthen Cepton’s business and develop our legal strategy to support our planned growth,” Anawalt said in the press release. “I look forward to being a part of Cepton’s journey in providing lidar-based solutions for a range of markets.” To view the full press release, visit https://ibn.fm/smrKg

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Monday's trading session at $2.83, off by 6.9079%, on 250,145 volume with 2.054 trades. The average volume for the last 3 months is 249,027 and the stock's 52-week low/high is $0.25/$1.00.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

  • Mullen called “dark horse” in HotCars 2022 list of top EV startups
  • Other online articles also shining spotlight on what CarBuzz calls “the real deal” 
  • Mullen CEO calls FIVE model “just the start”

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is starting the new year with a bang: the company is ranked no. 2 on the HotCars 2022 list of top-10 EV startups (https://ibn.fm/Gb5IR). Other online callouts have noted that Mullen is “making performance EVs to get excited about” (https://ibn.fm/anGC4) and have called Mullen “Tesla’s next potential competitor” (https://ibn.fm/5Bi4C). Like many companies across the world that rely on the global supply chain, Chinese electric vehicle maker Nio has revealed that it has been hit hard by the supply chain disruption caused by the coronavirus pandemic. Over the weekend, Nio announced that it would be raising the prices of the three electric SUVs it has on the market and halt production in the meantime. Nio’s shares fell by almost 9% following the announcement. Beginning May 10, Nio will increase the prices of its EC6, ES6 and ES7 by $1,572 (10,000 yuan). However, the recently unveiled ET5 and ET7 sedans will cost the same. According to NIO’s CEO William Li, raw material prices, especially for the minerals used to build electric vehicle batteries, have increased “too much” in 2021, and the company sees no downward trend in the near future. Aside from Nio, Li Auto and Xpeng, several other car makers have increased their prices as raw materials become more expensive and production costs rise. In the last couple of weeks, Tesla, WM Motors, BYD and SAIC-GM Wuling have raised the prices of their electric vehicles. We are yet to hear from other startups such as Mullen Automotive Inc. (NASDAQ: MULN) regarding the way in which they plan to navigate the current supply chain disruption. Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has announced plans to begin EV battery pack production out of its high voltage battery R&D facility located in Monrovia, California. In an effort to reduce dependency on third-party suppliers and reduce the risk associated with material and supply shortages, Mullen is retrofitting its Monrovia facility to accommodate the production of EV battery packs destined for the company’s EV vehicle lineup, including the ONE EV Cargo Van, FIVE EV Crossover and DragonFLY EV Sportscar programs. By taking production in-house, Mullen will also lower costs and increase overall quality control in battery pack development. “Building our own battery packs makes sense as it reduces our reliance on third-party suppliers and lessens our risk of being subjected to the waves of supply and critical component shortages,” said David Michery, CEO and chairman of Mullen Automotive. “The entire industry is struggling with supply chain issues and the more control we have in-house, the better off our vehicle programs will be. Our Monrovia facility is already established for high voltage applications so retrofitting it for our battery pack development makes good sense for our company and shareholders.” To view the full press release, visit https://ibn.fm/VuhvU.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Monday's trading session at $1.84, off by 14.8148%, on 108,971,994 volume with 164,330 trades. The average volume for the last 3 months is 108.972M and the stock's 52-week low/high is $0.0111/$0.133.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

  • World Intellectual Property Organization has published CYBN’s international patent application
  • Publication of patent application demonstrates CYBN’s continued commitment to discovering, developing psychedelic-based treatment options
  • Company continues to see strong protection for growing intellectual property portfolio of psychedelic-based compounds

Cybin (NEO: CYBN) (NYSE American: CYBN) announced that the World Intellectual Property Organization (“WIPO”) has published an international patent application filed by Cybin. According to Cybin, the application, titled "Methods for Delivery of Psychedelic Medications by Inhalation and Systems for Performing the Methods," further strengthens Cybin’s long-term intellectual property (“IP”) position related to psychedelic-based programs. A new study has found that consuming a healthy plant-based diet of legumes, nuts, vegetables, fruits and coffee is linked to a lower risk of developing type 2 diabetes. Healthy plant-based diets are rich in high-quality foods such as whole grains, vegetables and fruits. These diets have been linked to a lower risk of type 2 diabetes. Type 2 diabetes presents a major threat to health across the globe given that more than 90% of people with diabetes suffer from type 2 diabetes. Diabetes is mainly caused by unhealthy diets and genetic predisposition as well as being obese or overweight and other lifestyle factors, including not exercising. Diet seems to have a connection to lots of health conditions, including mental health disorders, which are growing to epidemic levels. Fortunately, several companies, including Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), are focused on addressing the need for superior therapeutics to combat the mental health crisis currently escalating at an alarming rate.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Monday's trading session at $0.778, off by 3.342%, on 689,011 volume with 1,329 trades. The average volume for the last 3 months is 685,870 and the stock's 52-week low/high is $0.0655/$0.32616.

Recent News

Home Bistro Inc. (OTC: HBIS)

The QualityStocks Daily Newsletter would like to spotlight Home Bistro Inc. (OTC: HBIS).

  • Home Bistro’s strategic acquisition of California-based Model Meals meal delivery brand created bicoastal operations
  • The company over the past 12 months has added five celebrity chefs to the Home Bistro platform
  • Home Bistro recently relocated its East Coast operations to a state-of-the-art South Florida food production and fulfillment facility, creating a highly cost-effective infrastructure
  • The company was selected best “a la carte” meal delivery service by Insider.com
  • Home Bistro recently launched a wine offering with In Good Taste Wines, a unique direct-to-consumer wine platform

Home Bistro (OTC: HBIS)  is a Miami-based company engaged in the business of providing prepackaged and prepared meals to consumers. The company has created the next generation of prepared meal delivery – Ready-Made Gourmet Meal Delivery 3.0.

Home Bistro Inc. (OTC: HBIS) is a Miami-based company engaged in the business of providing prepackaged and prepared meals to consumers. The company has created the next generation of prepared meal delivery – Ready-Made Gourmet Meal Delivery 3.0.

Home Bistro addresses the three major problems facing the prepared food delivery market: poor food quality; customers tired of eating the same meals; and, eating at home is still eating at home, with the accompanying food preparation and clean up chores. The company addresses these problems by delivering high quality food fresh and fast, providing customers a variety of meal choices from a diverse lineup of celebrity chefs, and requiring simple prep and easy clean up without sacrificing the fine dining experience.

Home Bistro offers a family of high quality, direct-to-consumer, ready-made, gourmet meals. Using the latest fresh food “skin-packing” technology, Home Bistro offers a virtual “Bistro Emporium” where consumers can cross select from a wide variety of siloed “bistros,” each with a dedicated section and unique visitor experience created by a renowned celebrity/executive chef. Meals delivered fresh can be eaten within 10 to 14 days or frozen for up to six months.

The company’s mission is to lead the next generation of heat-to-eat food delivery with unique and delicious cuisine and an experience that excites the market. Home Bistro’s advantage in the highly competitive meal delivery space is meal diversity – with the best celebrity chefs from around the world, offering a home-based fine dining experience through a selection of over 50 unique gourmet meals, as well as offering a developing selection of desserts and single-serving wine to perfectly complement the meal experience. In addition, the company uses only the highest quality ingredients in its meals and preserves their freshness by employing state-of-the-art vacuum skin packing.

In mid-2021, Home Bistro acquired southern-California based Model Meals, a lifestyle ready-to-eat meal prep service, which is Whole30 and Paleo approved, while then only serving three states. In September 2021, Home Bistro commenced shipping Model Meals to all 50 states and recently announced that it will launch a subscription-based service for Model Meals consisting of three meals per day (breakfast, lunch and dinner) for up to five days per week. The subscription service, expected to launch by May 2022, will initially target the Southern California market, where Model Meals maintains a food production and fulfillment facility and enjoys a strong customer base.

Brands and Products

Home Bistro’s leading online platform (www.homebistro.com) provides direct-to-consumer, heat-to-eat, celebrity chef-inspired gourmet meals. Offerings currently include inspirations developed by “Iron Chef” Cat Cora, two-time New York Times best-selling cookbook author and TV host Ayesha Curry, sports-tailgating focused creator of “Hungry Fan” Chef Diana Falk, “Master Chef” Claudia Sandoval, and “Top-Chef All-Star” Richard Blais. Soon-to-launch celebrity chefs on the Home Bistro platform include “Caterer to the Stars” Roblé Ali, “zero-waste cooking” celebrity chef Priyanka Naik, and CHOPPED champion Melanie Moss.

Home Bistro’s Model Meals lifestyle brand (www.modelmeals.com) is a Whole30 and Paleo approved, ready-to-eat meal prep service, offering a weekly rotating menu that is prepared by professional chefs, using only the highest quality ingredients available, sourced responsibly and locally, and delivered in sustainable, eco-friendly packaging.
Home Bistro has partnered with celebrity chef Melanie Moss to expand its dessert menu options. In keeping with its mission to deliver a complete gourmet culinary experience to discerning customers, Home Bistro beta-tested its first dessert – a delicious, sweet and salty caramel brownie. Based on the encouraging results, the company is moving forward to create a much more robust dessert menu.

Home Bistro has formally launched its wine offering initiative with In Good Taste Wines, a unique direct-to-consumer wine platform that empowers wine lovers to “discover the world, by the glass.” The company has worked diligently with the In Good Taste Wines team to develop a unique selection of elegant single-serving wines to pair with Home Bistro’s celebrity chef-inspired meals. The partnership with In Good Taste Wines provides Home Bistro with a low-cost, incremental source of revenue, which will assist the company in expanding its gross profit margin and lead it to faster profitability.

Market Outlook

Global revenue in the online food delivery sector was $136 billion in 2020 and forecast to grow steadily at a 7.5% CAGR through 2024 to a projected value of $182 billion.
In the U.S., the food delivery sector, which comprises both the restaurant-to-consumer segment and the platform-to-consumer segment where Home Bistro operates, is expected to surpass $32.3 billion in 2024. The company’s addressable market, the platform-to-consumer segment, is approximately 30% of the U.S. market and is projected to reach a value of $9.7 billion by 2024. This segment is expected to grow even faster than the sector as a whole as providers refine their focus on healthier meals, more convenient delivery and subscription options and more advanced meal processing technology.

Management Team

Zalmi Duchman is Chairman and CEO at Home Bistro. He was CEO and founder of The Fresh Diet online meal delivery service, which grew from a startup to over $30 million in annual revenue. He is a thought leader, investor and publisher of numerous articles in the food tech sector. He was named one of Forbes “America’s Most Promising CEOs Under 35,” and was named a Miami Herald “20 Under 40” entrepreneur in 2014.

Carlo Ricci is Director of Operations at Home Bistro. He was VP Operations for The Fresh Diet online meal delivery service, where he developed the culinary and R&D departments and established distribution centers in five states. He was also Operations Manager at Homemade Meals, where he developed and implemented inventory systems, established production facilities on both coasts and trained and managed personnel. He has a bachelor’s degree in data analytics from Miami Dade College.

Camille May is CFO at Home Bistro. She is a co-founder of Model Meals meal delivery service, where she has served as CFO since the company’s inception in 2015. She helped build the company from the ground up to more than $2 million in annual revenue. Prior to Model Meals, she worked as a financial analyst and broker in commercial real estate. She has a BBA in finance from the Leeds School of Business at the University of Colorado.

Danika Brysha is Chief Marketing Officer at Home Bistro. She co-founded Model Meals and was also a co-founder of the Self-Care Society. She is a former fashion model and founder of Danika Brysha Inc., a service specializing in modeling, coaching, speaking, events, media and influence. She is creator of the Brunch Series and a Whole30 certified coach. She is also host of the top-rated podcast “Light + Life Live” and is a lifestyle design expert. She earned a bachelor’s degree from the University of Colorado.

Home Bistro Inc. (OTC: HBIS), closed Monday's trading session at $0.5995, off by 0.083333%, on 504 volume with 4 trades. The average volume for the last 3 months is 504 and the stock's 52-week low/high is $0.0008/$0.0348.

Recent News

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF)

The QualityStocks Daily Newsletter would like to spotlight Red White & Bloom Brands Inc. (OTCQX: RWBYF).

Red White & Bloom (CSE: RWB) (OTCQX: RWBYF), a company positioning itself to be one of the top three multistate operators in the United States in cannabis and hemp-derived product lines, has adopted a strategy anchored in operating a house of brands as it anticipates the commoditization of the cannabis market. “This is going to be a commoditized market, and our strategy is such that we are going to stand on our brands going forward. We just need to fortify what we are doing in the markets that we are in right now,” a recent article quotes RWB CEO Brad Rogers in his closing remarks issued during a November corporate update call. “This company has been building… and we’ll catch up with respect to where we want to be. So, when we look across 2021, the new acquisitions, the markets, etc., we’ve been building towards that. We have now set the stage in the form of infrastructure to start reporting all revenues and assets of these businesses, most of the one-time expenses and large non-cash items are behind us, putting us on solid ground in 2022 and beyond.” To view the full article, visit https://cnw.fm/NzbMr

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) is a torchbearer blazing a new frontier in American cannabis by adhering to the highest ethical, manufacturing, educational, branding and employment standards available in the industry.

Red White & Bloom is a super state operator, leveraging a sizable footprint to dominate the areas in which it operates. CEO Brad Rogers and other management members have seen the struggles of multi-state operators who have spread themselves too thin, which is why Red White & Bloom is intent on dominating each state it enters before expanding further.

Although targeting individual states in the United States, the company is headquartered in Toronto, Canada. Red White & Bloom was established after privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019.

Brands

Red White & Bloom has entered strategic brand acquisitions and partnerships aimed at helping the company expand its presence and position as one of the largest players in the United States cannabis market. Red White & Bloom is always diligently searching for brands to acquire that will provide additional value to the company and expand its national footprint.

The company’s current brand portfolio includes:

  • Platinum Premium Cannabis Products (PV): Platinum uses innovative thinking, honesty and responsibility to remain at the forefront of the cannabis industry. PV holds itself and its partners to the highest standards, providing clean and safe CBD and THC products. In the company’s press release dated January 13, 2021, it reported system-wide sales of Platinum-branded products exceeding $2.8 million for the first week of January alone.
  • High Times®: In June 2020, the company acquired the licensing rights and branding of High Times dispensaries and High Times cannabis-based CBD and THC products in Michigan, Illinois and Florida. The company also acquired branding of High Times hemp derived CBD products nationally in the United States carrying the Culture® brand.
  • Mid-American Growers: Mid-American began as a family operation in 1971 in Granville, Illinois. The original 8-acre greenhouse has expanded to a 3.6-million-square-foot, state-of-the-art technology and science facility under glass. Mid-American’s product offerings include its CBD Icy Relief Salve, CBD Icy Relief Roll-on and CBD Gummies.

Retail Focus

Red White & Bloom is working to establish a significant retail presence across multiple jurisdictions. In Michigan, the company is invested in and has the rights to acquire (subject to regulatory approvals) a licensed operator that controls the assets of 18 dispensary locations throughout the state. Red White & Bloom is also pursuing opportunities in Florida aimed at making its proposed retail footprint compelling and attractive to the majority of cannabis consumers within each state.

Cultivation

Red White & Bloom is focused on standardization and quality, with everything guided by a relentless commitment to the highest standards. The company acquired a 3.6-million-square-foot standardized facility dedicated to helping it achieve premium value for the products it intends to cultivate.

As it continues to expand, the company remains committed to the practices that have guided its success in the past, including:

  • A top-down approach to cultivation developed under the guidance of PhDs with expertise in growing principles, SOPs and, most importantly, the science behind it all.
  • Commitment to exceeding the requirement of the states in which it operates. The company cut its teeth under the world’s first national cannabis purity regime – a regime that most new markets use as a benchmark – so quality is in its DNA.
  • Science-driven production methods supported by automated, perpetual, standardized operations that enable craft cannabis-like quality at an industrial scale.

Footprint

Assuming completion of the currently proposed investments and acquisitions, Red White & Bloom will be among the cannabis market’s largest companies, joining the ranks of a select few multi-state operators dominating the industry. Red White & Bloom currently has assets (closed and in closing stages) in Michigan, Illinois, Florida, California, Oklahoma and Massachusetts.

The company’s strategic acquisition and super state operator model, combined with its commitment to top-quality product and service, position it to become a leading player in the North American cannabis market.

When evaluated beside competitors in the cannabis space, Red White & Bloom boasts an extremely attractive valuation. While large cap cannabis firms serving North American markets averaged enterprise-value-to-EBITDA multiples of 14.9x as of December 2020, Red White & Bloom’s enterprise multiple was just 3.4x, as noted in the company’s latest investor deck.

In 2020, the cannabis market worldwide was valued at $24.6 billion. This amount is expected to expand at a CAGR of 14.3% from 2021 to 2028, resulting in a market size of $84 billion in 2028 (https://nnw.fm/f09ZL). Of the 2020 valuation, the largest revenue share (91.1%) was attributed to North American consumers (https://nnw.fm/vObW6).

Management Team

Brad Rogers is the CEO and Executive Chair of Red White & Bloom. He is a visionary for the future of cannabis and CBD products in the United States market, with a proven track record of building successful and profitable businesses in the rapidly expanding and new economic sector. Mr. Rogers was a part of the team that built one of the first commercially scaled production facilities in the world for medicinal cannabis. He also served as President for one of the leading licensed producers in Canada. Both of his ventures were successful, with a combined market cap of $2 billion.

Michael Marchese is the company’s Co-Founder and Marketing Advisor. He has played a crucial role in its development and organization, overseeing capital raises, acquisition strategy and brand identity. Mr. Marchese has a strong reputation and presence in the cannabis industry. He also co-founded and directed the branding of Aleafia Health Inc., which he continues to counsel. Through his branded company, Marchese Design, he has served as a highly trusted counselor to top-level execs, including C-Suite level employees, offering insights into the process of creating, building and maintaining brand identities.

Theo van der Linde is the CFO and Director of Red White & Bloom. He is a Chartered Accountant with 20 years of experience in finance, administration and public accounting. The experience he has acquired spans multiple industries, including mining, oil & gas, financial services, retail and manufacturing. For the last nine years, he has primarily focused his career on the mining industry, working with junior exploration and producing mining companies at various stages of growth in several jurisdictions. Mr. van der Linde is also the current President of Executive Management Solutions Ltd.

Red White & Bloom Brands Inc. (RWBYF), closed Monday's trading session at $0.2464, off by 1.7544%, on 148,117 volume with 40 trades. The average volume for the last 3 months is 148,117 and the stock's 52-week low/high is $ 0.22/$ 1.27.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Researchers have designed a machine learning model that can identify individuals suffering from PTSD by conducting an analysis of text data with 80% accuracy. Post-traumatic stress disorder (PTSD) is a mental health condition that is triggered by a traumatic event which an individual may witness or experience. This machine learning model may, in the future, be used as an inexpensive and accessible screening method to help physicians detect and diagnose post-traumatic stress disorder or other mental conditions, via telehealth platforms. Jeff Sawalha, a PhD candidate specializing in psychiatry at the University of Alberta, led this project. He carried out an analysis of text obtained from a dataset developed by a researcher at the Institute for Creative Technologies in USC. This sentiment analysis involved categorizing a huge body of data comprised of interview responses gathered over video conferencing calls with individuals who did and did not suffer from PTSD. As the diagnostic tools for various mental health conditions improve, there is also a need to speed up the development of new lines of treatment for these illnesses. Entities such as Silo Pharma Inc. (OTCQB: SILO) are responding to this need, and breakthroughs are imminent in the coming years.

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.

Research

Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Monday's trading session at $0.17, off by 19.0861%, on 285,328 volume with 60 trades. The average volume for the last 3 months is 285,328 and the stock's 52-week low/high is $4.32/$11.39.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) is among the organizations developing clean energy solutions to combat climate change. “On its part, FuelPositive aims to reduce the CO2 emissions from the production of grey ammonia. The company is developing a green ammonia production system that relies on renewable electricity to synthesize hydrogen from water and nitrogen from the air before combining the molecules in a proprietary converter to form ammonia. With over 80% of the world’s ammonia production being used in agriculture, FuelPositive’s system, which is portable, modular and scalable, could contribute to a substantial reduction in agriculture-related CO2 emissions directly linked to the production of grey ammonia,” a recent article reads. “At the same time, the system could provide on-demand fuel for the highly pollutive shipping and aviation industries.” To view the full article, visit https://ibn.fm/1I5mM

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Monday's trading session at $0.1205, off by 3.754%, on 367,367 volume with 48 trades. The average volume for the last 3 months is 367,367 and the stock's 52-week low/high is $0.133/$4.00.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

  • Delic opened two new KWC clinics in Q1 2022, bringing the total number of locations to 13, with plans to open more within the next 18 months
  • The company also saw the introduction of SPRAVATO(R) nasal spray as a treatment option for treatment-resistant depression
  • It is also expanding its ability to research novel compounds and develop IP for future commercialization

Delic Holdings' (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Chief Executive Officer (“CEO”) and Co-founder, Matt Stang, has been keen to note the company’s commitment to bringing psychedelic medicine closer to individuals dealing with mental health conditions, particularly those with treatment-resistant anxiety, depression, or post-traumatic stress disorder (“PTSD”).

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Monday's trading session at $0.04615, off by 9.6869%, on 101,463 volume with 17 trades. The average volume for the last 3 months is 101,463 and the stock's 52-week low/high is $0.014794/$0.13.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.